EA200500765A1 - Применение докозагексановой кислоты в качестве активного вещества для лечения липодистрофии - Google Patents

Применение докозагексановой кислоты в качестве активного вещества для лечения липодистрофии

Info

Publication number
EA200500765A1
EA200500765A1 EA200500765A EA200500765A EA200500765A1 EA 200500765 A1 EA200500765 A1 EA 200500765A1 EA 200500765 A EA200500765 A EA 200500765A EA 200500765 A EA200500765 A EA 200500765A EA 200500765 A1 EA200500765 A1 EA 200500765A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
lipodystrophy
active substance
acid
application
Prior art date
Application number
EA200500765A
Other languages
English (en)
Other versions
EA009711B1 (ru
Inventor
Хуан Карлос Доминго Педроль
Пере Доминго Педроль
Original Assignee
Проекто Эмпресариал Бруди, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проекто Эмпресариал Бруди, С.Л. filed Critical Проекто Эмпресариал Бруди, С.Л.
Publication of EA200500765A1 publication Critical patent/EA200500765A1/ru
Publication of EA009711B1 publication Critical patent/EA009711B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Применение экстракта животного, растительного происхождения или продуцируемого микроорганизмами, содержащего докозагексановую кислоту в качестве активного вещества, для производства медикамента для лечения липодистрофии у млекопитающих. Данное лечение эффективно и устраняет недостатки нынешних методов лечения липодистрофии у ВИЧ-инфицированных больных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500765A 2002-12-05 2003-12-01 Способ лечения липодистрофии у млекопитающего EA009711B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (2)

Publication Number Publication Date
EA200500765A1 true EA200500765A1 (ru) 2005-12-29
EA009711B1 EA009711B1 (ru) 2008-02-28

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500765A EA009711B1 (ru) 2002-12-05 2003-12-01 Способ лечения липодистрофии у млекопитающего

Country Status (24)

Country Link
US (1) US8202906B2 (ru)
EP (1) EP1585513B1 (ru)
JP (1) JP2006511514A (ru)
KR (1) KR100906086B1 (ru)
CN (1) CN100355421C (ru)
AT (1) ATE326959T1 (ru)
AU (1) AU2003302679B2 (ru)
BR (1) BR0316973A (ru)
CA (1) CA2506993C (ru)
CY (1) CY1105205T1 (ru)
DE (1) DE60305534T2 (ru)
DK (1) DK1585513T3 (ru)
EA (1) EA009711B1 (ru)
ES (2) ES2209658B1 (ru)
IL (1) IL168766A (ru)
IS (1) IS2384B (ru)
MX (1) MXPA05005911A (ru)
NO (1) NO20052960L (ru)
NZ (1) NZ540262A (ru)
PL (1) PL377563A1 (ru)
PT (1) PT1585513E (ru)
UA (1) UA79650C2 (ru)
WO (1) WO2004050077A1 (ru)
ZA (1) ZA200503872B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CN103372215B (zh) 2008-01-03 2016-03-09 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
US20020016314A1 (en) * 2000-01-31 2002-02-07 Schersl Endre Markovits Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
DK1157692T3 (da) * 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
CY1105205T1 (el) 2010-03-03
IS2384B (is) 2008-07-15
UA79650C2 (en) 2007-07-10
KR100906086B1 (ko) 2009-07-06
ES2265607T3 (es) 2007-02-16
PL377563A1 (pl) 2006-02-06
CN100355421C (zh) 2007-12-19
IL168766A (en) 2009-11-18
AU2003302679A1 (en) 2004-06-23
DK1585513T3 (da) 2006-09-18
EP1585513B1 (en) 2006-05-24
DE60305534T2 (de) 2007-05-16
ATE326959T1 (de) 2006-06-15
JP2006511514A (ja) 2006-04-06
CN1720039A (zh) 2006-01-11
DE60305534D1 (de) 2006-06-29
EA009711B1 (ru) 2008-02-28
AU2003302679B2 (en) 2009-01-15
KR20050085313A (ko) 2005-08-29
US8202906B2 (en) 2012-06-19
ES2209658A1 (es) 2004-06-16
CA2506993C (en) 2010-04-13
NZ540262A (en) 2006-11-30
PT1585513E (pt) 2006-10-31
WO2004050077A1 (en) 2004-06-17
BR0316973A (pt) 2005-10-25
CA2506993A1 (en) 2004-06-17
ZA200503872B (en) 2006-08-30
US20060178436A1 (en) 2006-08-10
EP1585513A1 (en) 2005-10-19
NO20052960L (no) 2005-06-16
MXPA05005911A (es) 2005-08-29

Similar Documents

Publication Publication Date Title
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
EA200201012A1 (ru) Способы стерилизации биологических материалов
ATE482712T1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
DE60107065D1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
EA200201214A1 (ru) Замещенные тиоацетамиды
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
DE69940975D1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
SE0950392L (sv) Sammansättning för behandling av hudåkommor
WO2002015844A3 (en) Antimicrobial composition and methods of use in the treatment of disease
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
EA200400888A1 (ru) Фармацевтически приемлемые тельца, несущие фосфат глицерина
EA200500765A1 (ru) Применение докозагексановой кислоты в качестве активного вещества для лечения липодистрофии
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
NO20054912L (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU